ClinicalTrials.gg
Active, not recruitingNCT05221840PACIFIC-9Updated Nov 4, 2026

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

A Phase 3 interventional study of Durvalumab and Oleclumab in Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 202 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Updated Nov 4, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,051
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca — 25 open to participants now, 78 under way, 28 of them phase 3. Carcinoma, Non-Small-Cell Lung · AstraZeneca.

Enrollment
9th of 137
1,051 · median 152
Started
2022
with 13 others
Phase 3
44 of 209
6 open now
Primary completion
2027-01
later than 43 of 77 live
Registered
155th of 209
by date

Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 9th largest by enrollment of the 137 interventional ones that give a count, is one of 14 that started in 2022, is one of 44 in phase 3, reaches primary completion later than 43 of the 77 other live ones, and was the 155th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

25 of the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, or all of them as a file.
02

Study summary

This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Non-Small Cell Lung Cancer
  • Locally Advanced NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥ 18 years at the time of screening.
  • - or cytologically-documented NSCLC and have been treated with concurrent CRT for locally advanced, unresectable (Stage III) disease
  • Provision of a tumour tissue sample obtained prior to CRT
  • Documented tumour status by central lab
  • Documented EGFR and ALK wild-type status (local or central).
  • Patients must not have progressed following definitive, platinum based, concurrent chemoradiotherapy
  • Participants must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy
  • Participants must have received a total dose of radiation of 60 Gy ±10% (54 Gy to 66 Gy) as part of the chemoradiation therapy, to be randomised. Radiation therapy should be administered by intensity modulated RT (preferred) or 3D-conforming technique.
  • of 0 or 1 at randomization
  • Adequate organ and marrow function

Exclusion criteria

EXCLUSION CRITERIA:

  • History of another primary except for malignancy treated with curative intent with no known active disease ≥5 years before the first dose of study intervention and of low potential risk for recurrence, adequately resected non-melanoma skin cancer and curatively treated in situ disease, or adequately treated carcinoma in situ or Ta tumours without evidence of disease.
  • Mixed small cell and non-small cell lung cancer histology.
  • Participants who receive sequential (not inclusive of induction) chemoradiation therapy for locally advanced (Stage III) unresectable NSCLC.
  • Participants with locally advanced (Stage III) unresectable NSCLC who have progressed during platinum-based cCRT.
  • Any unresolved toxicity >Grade 2 from the prior chemoradiation therapy (excluding alopecia).
  • Participants with ≥grade 2 pneumonitis from prior chemoradiation therapy.
  • History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, or idiopathic pneumonitis - regardless of time of onset prior to randomisation. Evidence of active non-CRT induced pneumonitis (≥ Grade 2), active pneumonia, active ILD, active or recently treated pleural effusion, or current pulmonary fibrosis - diagnosed in the past 6 months prior to randomization.
  • Active or prior documented or inflammatory disorders (with exceptions)
  • Current or prior use of medication within 14 days before the first dose of durvalumab.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,051 participants (actual)

Study arms

  • Experimental
    Arm A: Durvalumab and Oleclumab

    Durvalumab on Day 1 of each 28-day cycle + Oleclumab on Days 1 and 15 of cycles 1 and 2, then on Day 1 of each subsequent 28-day cycle for up to 12 months

    Drug: Durvalumab · Drug: Oleclumab

  • Experimental
    Arm B: Durvalumab and Monalizumab

    Durvalumab + Monalizumab on Day 1 of each 28-day cycle for up to 12 months. Placebo infusion will be administered on Day 15 of cycles 1 and 2 only

    Drug: Durvalumab · Drug: Monalizumab · Other: Placebo

  • Active comparator
    Arm C: Durvalumab and Placebo

    Durvalumab on Day 1 of each 28-day cycle + Placebo on Days 1 and 15 of cycles 1 and 2, then on Day 1 of each subsequent 28-day cycle for up to 12 months

    Drug: Durvalumab · Other: Placebo

Interventions

  • Durvalumab IV (intravenous infusion)

  • Oleclumab IV (intravenous infusion)

  • Monalizumab IV (intravenous infusion)

  • OtherPlacebo

    Placebo IV (intravenous infusion)

06

What researchers measure

Primary outcomes

  1. Progression Free Surival (PFS)

    Progression Free Survival (PFS) as assessed by BICR, per RECIST 1.1.

    Time frame: Up to 5 years after first patient randomized.

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival (OS)

    Time frame: Up to 9 years after first patient randomized

  2. Objective response rate (ORR)

    Objective response rate (ORR) per RECIST 1.1 as assessed by BICR

    Time frame: Up to 5 years after first patient randomized

  3. Overall survival (OS) at 24 months

    Overall survival (OS) at 24 months

    Time frame: Up to 9 years after first patient randomized

  4. Duration of response (DoR)

    Duration of response (DoR) per RECIST 1.1 as assessed by BICR

    Time frame: Up to 5 years after first patient randomized

  5. Progression free survival (PFS) at 6, 12, 18, and 24 months

    Progression free survival (PFS) at 6, 12, 18, and 24 months respectively, per RECIST 1.1 as assessed by BICR

    Time frame: From date of randomization until 24 months

  6. Time from randomization to second progression (PFS2)

    Time from randomization to second progression (PFS2)

    Time frame: Up to 5 years after first patient randomized

  7. Time from randomization to first date of distant metastasis or death (TTDM)

    Time from randomization to first date of distant metastasis or death (TTDM)

    Time frame: Up to 5 years after first patient randomized

  8. Time from randomization to start date of first subsequent therapy (TFST)

    Time from randomization to start date of first subsequent therapy (TFST)

    Time frame: Up to 9 years after first patient randomized

  9. Progression free survival (PFS) as assessed by Investigator

    Progression free survival (PFS) as assessed by Investigator

    Time frame: Up to 5 years after first patient randomized

  10. IHC analysis of PD-L1 TC expression

    IHC analysis of PD-L1 TC expression relative to efficacy outcomes

    Time frame: Up to 5 years after first patient randomized

  11. Concentration of Durvalumab

    To assess the Pharmacokinetics of Durvalumab when in combination with Monalizumab or Oleclumab - serum peak and trough concentrations

    Time frame: From date of randomization until 3 months after date of last IP dose

  12. Anti-drug antibodies (ADAs)

    The immunogenicity of durvalumab, oleclumab, and monalizumab as assessed by presence of anti-drug antibodies (ADAs)

    Time frame: From date of randomization until 3 months after date of last IP dose

  13. Time to deterioration in pulmonary symptoms (TTFCD)

    Time to deterioration in pulmonary symptoms (TTFCD)

    Time frame: Up to 5 years after last patient randomized

  14. Concentration of Oleclumab

    To assess the Pharmacokinetics of Oleclumab when in combination with Durvulumab - serum peak and trough concentrations

    Time frame: From date of randomization until 3 months after last dose of IP

  15. Concentration of Monalizumab

    To assess the Pharmacokinetics of Monalizumab when in combination with Durvalumab - serum peak and trough concentrations

    Time frame: From date of randomization until 3 months after last dose of IP

07

Study locations

202 sites
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Stuart, Florida 34994, United States
  • Research Site
    Urbana, Illinois 61801, United States
  • Research Site
    New Albany, Indiana 47150, United States
  • Research Site
    Lexington, Kentucky 40503, United States
  • Research Site
    Louisville, Kentucky 40241, United States
  • Research Site
    Annapolis, Maryland 21401, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Baltimore, Maryland 21229, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Grand Rapids, Michigan 49503, United States
  • Research Site
    Duluth, Minnesota 55805, United States
  • Research Site
    Billings, Montana 59101, United States
  • Research Site
    Ridgewood, New Jersey 07450, United States
  • Research Site
    Ithaca, New York 14850, United States
  • Research Site
    Greensboro, North Carolina 27403, United States
  • Research Site
    Cleveland, Ohio 44124, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Maumee, Ohio 43537, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    York, Pennsylvania 17403, United States
  • Research Site
    Sioux Falls, South Dakota 57105, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Charlottesville, Virginia 22908, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Fredericksburg, Virginia 22408, United States
  • Research Site
    Richmond, Virginia 23235, United States
  • Research Site
    Richland, Washington 99352, United States
  • Research Site
    Spokane, Washington 99204, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States
  • Research Site
    Box Hill, 3128, Australia
  • Research Site
    East Melbourne, 3002, Australia
  • Research Site
    Elizabeth Vale, 5112, Australia
  • Research Site
    Gosford, 2250, Australia
  • Research Site
    Heidelberg, 3084, Australia
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    South Brisbane, 4101, Australia
  • Research Site
    St Albans, 3021, Australia
  • Research Site
    Westmead, 2145, Australia
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Belo Horizonte, 30380-090, Brazil
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Fortaleza, 60336-232, Brazil
  • Research Site
    Jaú, 17210-120, Brazil
  • Research Site
    Natal, 59075-740, Brazil
  • Research Site
    Porto Alegre, 90610-001, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Recife, 52010-075, Brazil
  • Research Site
    São Paulo, 01323-903, Brazil
  • Research Site
    Uberlândia, 38408-150, Brazil
  • Research Site
    Vitória, 29043-260, Brazil
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Barrie, Ontario L4M 6M2, Canada
  • Research Site
    Hamilton, Ontario L8V 5C2, Canada
  • Research Site
    Kingston, Ontario K7L 2V7, Canada
  • Research Site
    London, Ontario N6A 5W9, Canada
  • Research Site
    Mississauga, Ontario L5M 2N1, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Rimouski, Quebec G5L 5T1, Canada
  • Research Site
    Anyang, 455000, China
  • Research Site
    Beijing, 100021, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510062, China
  • Research Site
    Guangzhou, 510700, China
  • Research Site
    Hangzhou, 310002, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Hefei, 133500, China
  • Research Site
    Hefei, 230031, China
  • Research Site
    Kunming, 650118, China
  • Research Site
    Linhai, 317000, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Nantong, 226361, China
  • Research Site
    Neijiang, 641000, China
  • Research Site
    Ningbo, 315100, China
  • Research Site
    Shaoguan, 512027, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430071, China
  • Research Site
    Wuhan, 430079, China
  • Research Site
    Zhanjiang, 524001, China
  • Research Site
    Zhengzhou, 450000, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Zhongshan, 528403, China
  • Research Site
    Barranquilla, 080020, Colombia
  • Research Site
    Bogota D.C., 110131, Colombia
  • Research Site
    Medellín, 050034, Colombia
  • Research Site
    Valledupar, 200001, Colombia
  • Research Site
    Avignon, 84918, France
  • Research Site
    Besançon, 25030, France
  • Research Site
    Bordeaux, 33075, France
  • Research Site
    Clermont-Ferrand, 63000, France
  • Research Site
    Créteil, 94010, France
  • Research Site
    Lorient, 56322, France

Showing the first 100 of 202 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Barlesi F, Cho BC, Goldberg SB, Yoh K, Zimmer Gelatti AC, Mann H, Gopinathan A, Bielecka ZF, Newton M, Aggarwal C. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer. Future Oncol. 2024;20(29):2137-2147. doi: 10.1080/14796694.2024.2354160. Epub 2024 Jul 18. PubMed 39023287 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Jan 2027, 59 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 59 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2022
First posted
Feb 3, 2022
StartActual
Feb 7, 2022
Primary completionEst.
Jan 8, 2027was Sep 2026
CompletionEst.
Jul 2, 2030
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Jan 8, 2027
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Primary completion Sep 30, 2026→Jan 8, 2027
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05221840
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 3, 2022
Start date
Feb 7, 2022
Primary completion
Jan 8, 2027 (estimated)
Completion
Jul 2, 2030 (estimated)
Last update
Nov 4, 2026

Study contacts

Fabrice Barlesi, MD
principal investigator · Gustave Roussy, Cancer Campus, Grand Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oleclumab · Monalizumab

Start the discussion